Sign In
Buy MRNA
$59.81
+0.640 (+1.08%)
At Close: Aug 10, 2026
Moderna (MRNA) Stock Dips While Market Gains: Key Facts
06:46pm, Tuesday, 23'rd Dec 2025
The latest trading day saw Moderna (MRNA) settling at $32.29, representing a -7.48% change from its previous close.
Stocks Pare Losses, Brush Off Rate Cut Concerns
12:21pm, Tuesday, 23'rd Dec 2025
Stocks are recovering from morning losses, with all three major indexes now eyeing four-straight wins
Top large-cap gainers for Dec. 15-19 were led by Rivian, Moderna, and BioMarin, rising on product/software updates, vaccine funding news, and a major acquisition deal, with Rocket Lab, Affirm, and cru
MRNA to Get CEPI Funding for Phase III Study on Pandemic Influenza Jab
11:10am, Friday, 19'th Dec 2025
Moderna secures up to $54.3 million from CEPI to fund a pivotal phase III study of its mRNA-based H5 pandemic flu vaccine candidate, mRNA-1018.
Down 80%, Should You Buy the Dip on Moderna?
04:10am, Friday, 19'th Dec 2025
Moderna's earnings and stock price climbed during early pandemic days -- that's as demand for the company's coronavirus vaccine soared. Since, the company has faced various challenges that have weighe
Moderna's $54M Lifeline: Bird Flu Bet Revived After U.S. Pullback
12:32pm, Thursday, 18'th Dec 2025
Funding support from outside groups could be opening a new chapter for Moderna (MRNA) as the company advances its bird flu vaccine program amid a shifting US re
Moderna secures up to $54.3 million funding for bird flu vaccine from global coalition
07:02am, Thursday, 18'th Dec 2025
Moderna will get up to $54.3 million in funding from a global coalition to support late-stage development of its experimental bird flu vaccine, the U.S. drugmaker said on Thursday.
CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate
07:00am, Thursday, 18'th Dec 2025
Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure Partnership strengthens global preparedness against a significant pandemic threa
Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference
07:00am, Wednesday, 17'th Dec 2025
CAMBRIDGE, MA / ACCESS Newswire / December 17, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced it will present at the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12th at 7:30 p
CHMP Backs EU Approval of MRNA's New COVID-19 Vaccine mNexspike
10:56am, Tuesday, 16'th Dec 2025
CHMP backs EU approval of Moderna's next-generation mNexspike COVID-19 vaccine, with a final European Commission decision expected shortly.
mNEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine) mNEXSPIKE will be available in the
Market Today: Tech Slumps, Broadcom Tanks; EU Eases ICE Ban
05:35pm, Friday, 12'th Dec 2025
Stock News Tech-led selloff caps tough week: US stocks fell as investors rotated out of mega-cap tech after Broadcom (AVGO) and Oracle (ORCL) stoked AI-spending
FDA Weighs Black Box Warning For COVID Vaccines, Experts Push Back
01:51pm, Friday, 12'th Dec 2025
FDA officials are weighing a black box warning for Covid vaccines, a proposal that has drawn strong criticism from outside experts citing lack of evidence.
Moderna 2026 Covid and RSV growth not enough to boost stock, Jefferies says
11:42am, Friday, 12'th Dec 2025
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) has been awarded a ‘Hold' rating and $30 price target, implying limited upside, from Jefferies analysts in their initial coverage of the drugmaker. Moderna share
Pre-Market Stock Futures: The futures are trading mixed as we get set to close out a wild and woolly week that saw a touch of just about everything. The Federal Reserve, as expected, cut rates again a
